Rubius Therapeutics, Inc.

DB:5RT Stock Report

Market Cap: €1.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rubius Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure2.1yrs

Recent management updates

Recent updates

CEO

Craig Jalbert (61 yo)

less than a year

Tenure

Mr. Craig R. Jalbert, CIRA is President, Treasurer, Corporate Secretary & Director of Aptinyx Inc. since May 04, 2023. He is President, Treasurer, Corporate Secretary, Principal Executive Officer, Interim...

Board Members

NamePositionTenureCompensationOwnership
Craig Jalbert
Presidentless than a yearno datano data
Michael Rosenblatt
Independent Director8.5yrsUS$421.66k0%
€ 0
Robert Langer
Member of Scientific Advisory Board8.5yrsUS$850.74kno data
Harvey Lodish
Scientific Advisory Board5.3yrsUS$24.00kno data
Gerald Nepom
Member of Scientific Advisory Board2.1yrsno datano data
Vijay Kuchroo
Member of Scientific Advisory Board2.1yrsno datano data
Susanne Schaffert
Directorless than a yearno datano data
Francis Cuss
Independent Director5.4yrsUS$426.66k0%
€ 0
Christopher Carpenter
Member of Scientific Advisory Board3.4yrsUS$2.84mno data
Christopher Hunter
Member of Scientific Advisory Board2.1yrsno datano data
John Monroe
Member of Scientific Advisory Board2.1yrsno datano data

2.1yrs

Average Tenure

68yo

Average Age

Experienced Board: 5RT's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.